To explore the treatment of patients with early localized prostatic carcinoma, we surveyed the departments of urology and general surgery in Denmark, Finland, Norway, and Sweden. Clinical policies and physicians' attitudes toward the radical treatment options varied widely between the countries. A correlation seems to exist between practice patterns and national attitudes toward special technologies.

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0266462300005262DOI Listing

Publication Analysis

Top Keywords

clinical policies
8
policies physicians'
8
physicians' attitudes
8
attitudes radical
8
radical treatment
8
treatment options
8
management early
4
early prostatic
4
prostatic cancer
4
cancer nordic
4

Similar Publications

The objective of this study is to gain insight into the current research frontiers, hotspots, and development trends in the field of immunization programs for women and children, and to provide scientific guidance and reference for follow-up research. Based on all the original research papers related to the research on immunization programs for women and children in the Web of Science Core Collection (WoSCC) database, bibliometric studies and visual analysis were carried out to explore the research frontiers, hotspots and development trends, and to analyze the risk factors affecting the vaccination coverage of immunization programs for women and children. Eight hundred forty-three papers obtained from 1,552 institutions in 96 countries/regions from January 1950 to August 2024, coauthored by 4,343 authors.

View Article and Find Full Text PDF

A New Way Forward for Women's Health Research at the National Institutes of Health: A Roadmap From the National Academies of Sciences, Engineering, and Medicine's Consensus Report.

Obstet Gynecol

January 2025

Department of Obstetrics and Gynecology, Spencer Fox Eccles School of Medicine, University of Utah Health, Salt Lake City, Utah; the Department of Obstetrics and Gynecology, Warren Alpert Medical School at Brown University, and Women and Infants Hospital of Rhode Island, Providence, Rhode Island; the National Academies of Sciences, Engineering, and Medicine, and Baker Donelson, Washington, DC; KFF, San Francisco, California; and the Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke School of Medicine, Durham, North Carolina. All authors served on the National Academies Committee as committee members or employees of the National Academies.

Despite efforts to address inequities, research on women's health conditions (defined as those that uniquely or differently affect women and female individuals) remain significantly understudied. As directed by Congress, the National Institutes of Health (NIH) Office of Research on Women's Health requested the National Academies of Sciences, Engineering, and Medicine (National Academies) to conduct an assessment of the state of women's health research at the NIH. The findings of the National Academies committee include: 1) a significant funding inequity, with less than 8% of the total NIH grant budget for fiscal year 2023 allocated to women's health research; 2) a need for improved strategic NIH-wide priority setting, oversight, and adherence to existing policies to support women's health research; 3) a need for a specific institute for research on conditions specific to women's health; and 4) a need for sufficient training and additional funding to grow and retain the women's health research workforce.

View Article and Find Full Text PDF

Background: : With more than 60 million new cases around the world each year, traumatic brain injury (TBI) causes substantial mortality and morbidity. Managing TBI is a major human, social, and economic concern. In the last 20 years, there has been an increase in clinical trials in neurocritical care, leading mostly to negative results.

View Article and Find Full Text PDF

Melanoma is an aggressive tumor that is challenging to treat. Talimogene laherparepvec (T-VEC), the first oncolytic virus treatment approved by the US Food and Drug Administration to treat unresectable melanoma, was recently used in recurrent tumors after initial surgery. Our network meta-analysis aimed to compare T-VEC treatment of metastatic melanoma with treatment of granulocyte-macrophage colony-stimulating factor (GM-CSF) and control group.

View Article and Find Full Text PDF

Background: The Wound Care Collaborative Community (WCCC) assesses shortcomings and unmet needs in wound care by partnering with key stakeholders, such as the National Institutes of Health, the US Food and Drug Administration (FDA), industry leaders, and expert health care providers and researchers, to advance the study of wound healing. Through this work, the WCCC has identified a few key barriers to innovation in wound care. The WCCC aims to accelerate the development of science-based, patient-centered solutions and address public policy challenges related to ensuring patients receive early access to innovative treatment options.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!